Philip Morris International Raises Dividend by 8.9% to an Annualized $5.88 per Share

Sep.24.2025

Philip Morris International (PMI) has increased its quarterly dividend from $1.35 to $1.47 per share, bringing the annualized dividend to $5.88. Since listing in 2008, PMI has raised its dividend for 17 consecutive years. The company continues to accelerate its “smoke-free future” strategy: in the first half of 2025, smoke-free products contributed 41% of net revenues, with over 41 million adult consumers using PMI’s smoke-free products globally.

Key Points

Increase: Quarterly dividend lifted from $1.35 to $1.47 (+8.9%), annualized $5.88.
Key dates: Record date and ex-dividend date: October 3, 2025; payment date: October 20, 2025.
Shareholder returns: Dividend raised every year since 2008; +219.6% cumulative increase; ~7.1% CAGR.
Business mix: Smoke-free accounted for 41% of H1 2025 net revenues; user base >41 million.
Investment & regulation: More than $14 billion invested in R&D and commercialization of smoke-free products since 2008; FDA marketing authorizations for versions of IQOS devices/consumables and for Swedish Match’s General snus and ZYN nicotine pouches; some products hold MRTP (modified-risk) orders.
Strategy: Alongside smoke-free growth, PMI is exploring long-term opportunities in wellness and healthcare.

2Firsts, September 24, 2025 — PMI announced that its Board of Directors has approved an increase in the regular quarterly dividend to $1.47 per share from $1.35, resulting in an annualized dividend of $5.88. The dividend will be paid on October 20, 2025 to shareholders of record as of October 3, 2025; the ex-dividend date is also October 3, 2025.

PMI noted that it has increased its annual dividend every year since becoming a public company in 2008, representing a 219.6% cumulative increase and a compound annual growth rate of about 7.1%. Management said the company’s consistent shareholder returns go hand in hand with its transition toward a smoke-free future.

On the business mix, PMI’s portfolio includes both traditional cigarettes and smoke-free products (heat-not-burn, nicotine pouches and e-vapor). As of June 30, 2025, PMI estimates that over 41 million legal-age consumers use its smoke-free products, many of whom have quit or significantly reduced cigarette consumption. Smoke-free products contributed 41% of PMI’s total net revenues in the first half of 2025. Since 2008, PMI has invested $14+ billion in developing, scientifically substantiating and commercializing smoke-free products, and has built capabilities spanning toxicology, clinical and behavioral research, as well as post-market studies.

On the regulatory front, the U.S. FDA has authorized the marketing of Swedish Match’s General snus and ZYN nicotine pouches, and versions of PMI’s IQOS devices and consumables; some variants of IQOS and General have also received Modified Risk Tobacco Product (MRTP) orders. Leveraging its life-science foundation, PMI said it will continue exploring wellness and healthcare opportunities while advancing the goal of ultimately ending the sale of cigarettes.

References:

[1] Philip Morris International Increases Dividend by 8.9% to Annualized Rate of $5.88 per Share

Also Read:

[1] Philip Morris International's five-year EU investment exceeds €43 billion, generating nearly €290 billion in economic impact

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com